EMA Authorised: Osenvelt (denosumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorised Osenvelt (denosumab) by Celltrion Healthcare Hungary Kft. for Giant Cell Tumor of Bone and other bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Osenvelt (denosumab)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 15/01/2026